Transforming growth factor alpha, amphiregulin and cripto- 1 are frequently expressed in advanced ovarian carcinomas

d'Antonio, Antonio and Losito, Simona and Pignata, Sandro and Grassi, Michele and Perrone, Francesco and de Luca, Antonella and Tambaro, Rosa and Bianco, Caterina and Gullick, William J. and Johnson, Gibbes R. and Iaffaiola, Vincenzo R. and Salomon, David S. and Normanno, Nicola (2002) Transforming growth factor alpha, amphiregulin and cripto- 1 are frequently expressed in advanced ovarian carcinomas. International Journal of Oncology, 21 (5). pp. 941-948. ISSN 1019-6439 . (The full text of this publication is not available from this repository)

The full text of this publication is not available from this repository. (Contact us about this Publication)

Abstract

The expression of transforming growth factor alpha (TGFalpha), amphiregulin (AR) and cripto-1 (CR-1) was assessed by immunohistochemistry in 83 specimens (59 primary ovarian tumors and 24 extra-ovarian carcinomas) that were obtained from 68 ovarian carcinoma patients. Within the 59 primary tumors, 54 (92%) expressed immunoreactive TGFalpha, 45 (76%) expressed AR, and 28 (47%) expressed CR-1. The expression of AR and CR-1 mRNAs in the ovarian carcinomas was also demonstrated by RT-PCR analysis. Seventeen extra-ovarian specimens (71%) were found to express CR-1, whereas AR and TGFalpha were expressed respectively in 21 (87%) and 22 (92%) extra-ovarian tissues. In 15 cases for whom both ovarian and extra-ovarian tissues were available, a statistically significant higher expression of CR-1 was found in extra-ovarian specimens. A statistically significant correlation was found between AR expression in the ovarian carcinomas and both low grade and low proliferative activity. Finally, expression of TGFalpha was predictive of longer progression-free survival. These data strongly suggest that the EGF-related peptides might be involved in the pathogenesis and outcome of human ovarian cancer.

Item Type: Article
Uncontrolled keywords: cripto-1; amphiregulin; TGF alpha; ovarian cancer; prognosis
Subjects: Q Science
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Faculties > Science Technology and Medical Studies > School of Biosciences > Biomedical Research Group
Depositing User: Bill Gullick
Date Deposited: 25 Sep 2009 13:18
Last Modified: 15 May 2014 15:28
Resource URI: http://kar.kent.ac.uk/id/eprint/22655 (The current URI for this page, for reference purposes)
  • Depositors only (login required):